Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor
(CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical …

Background Selinexor combined with dexamethasone has shown activity in patients with
heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor …

Despite treatment advances, patients with multiple myeloma (MM) often progress through
standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), …

Given the immune system's importance for cancer surveillance and treatment, we have
investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some …

Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in
achieving a complete remission in a range of B-cell malignancies, most notably B-acute …

2. Thachil J. What do monitoring platelet counts in COVID-19 teach us? J Thromb Haemost.
2020. https://doi. org/10.1111/jth. 14879 3. Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, …

Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has highlighted
the clinical relevance of LN fibroblast and tumor-infiltrating lymphocyte (TIL) signatures …

Hematological toxicity is the most common adverse event after chimeric antigen receptor (CAR)
T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

Background Using an updated dataset with more patients and extended follow-up, we further
established cancer patient characteristics associated with COVID-19 death. Methods Data …

Background The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic
leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric …